Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.68 -6.76%
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $268.06 million versus the consensus estimate of $280.92 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.23 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
- Roth/MKM Starts Buda Juice Inc. (BUDA) at Buy
- Nomura/Instinet Starts Great Eastern Shipping (GESCO:IN) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
